Development of a new generation of immunomodulators

In 2012, two Chinese scientists who launched a start-up named Connect Biopharmaceuticals having facilities in Shanghai, Melbourne, Australia and San Diego managed to collect $ 115 million US within the series C funding. This fresh investment will help the scientists to advance clinical programs for the development of modernized immunomodulators. Monoclonal antibodies CBP-201 and CBP-307 are currently being developed in a phase II study for Crohn's disease and ulcerative colitis. The scientists assure that their molecules will work for other inflammatory autoimmune diseases as well.

For the treatment of atopic dermatitis, CBP-201 (S1P1 receptor modulator inhibiting the synthesis of a specific interleukin subtype IL-4Rα) was originally developed. It has been shown to be effective in this condition in moderate trials. It relieved itchy skin lesions in patients with moderate to severe atopic dermatitis in as little as four weeks.

SOURCE: ENDPOINTS NEWS